NCT06530251 2026-03-04
A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)
Akeso
Phase 1/2 Recruiting
Clinical Trials
13 trialsNCT07331883 2026-01-21
Sintilimab Combined With Bevacizumab Biosimilar as Adjuvant Treatment After Resection of Ruptured Hepatocellular Carcinoma (CLEAR-2)
Ruijin Hospital
Phase 2 Recruiting
NCT07157969 2025-12-01
ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC
Peking Union Medical College Hospital
Phase 2 Recruiting
NCT07186621 2025-09-22
Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3 Recruiting
NCT06031285 2025-07-23
Perioperative Sintilimab Plus Bevacizumab Biosimilar and TACE-HAIC for HCC Patients With PVTT: A Phase-2 Clinical Trial
Sun Yat-sen University
Phase 2 Recruiting
NCT06860490 2025-03-26
HAIC Combined with Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03)
Fudan University
Phase 2 Recruiting
NCT05713994 2025-03-25
CCGLC-001
Tongji Hospital
Recruiting
NCT06333561 2025-02-06
HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma
Sun Yat-sen University
Recruiting
NCT06558227 2024-12-16
Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 2 Recruiting
NCT06313190 2024-11-18
HSBRT2402
Sun Yat-sen University
Phase 2 Recruiting
NCT06664996 2024-10-30
Sintilimab Combined SBRT As Neoadjuvant Therapy for Resectable HCC with PVTT
West China Hospital
Phase 2 Recruiting
NCT05992584 2023-09-14
Lenvatinib, Sintilimab Plus SIRT for Unresectable HCC
Second Affiliated Hospital of Guangzhou Medical University
Phase 2 Recruiting
NCT05608200 2023-05-31
Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC
Second Affiliated Hospital of Guangzhou Medical University
Phase 3 Recruiting